Much better for us to stay down here and turn that .30 into 1.00 instead of fighting a ton of short interest and trying for less than a double for $15.00.
And regardless of the share structure - no one will pay $15 a share for this even with lympro. It's simply too high a share price for a company with one product that's unproven in the market.